EU majority says same INNs for biosimilars

Biosimilars/General | Posted 28/02/2014 post-comment0 Post your comment

According to recently published summary minutes from an October 2013 meeting of the European Commission’s Pharmaceutical Committee, the majority of EU Member States agree that biosimilars should have the same international non-proprietary name (INN) as their reference biological.

Biologicals 1 NAME V13J31

The agenda point was discussed, during the 71st Pharmaceutical Committee meeting held on 23 October 2013 in Brussels, Belgium, as a result of industry stakeholders seeking support for the ongoing discussions over the use of an INN qualifier for biosimilars in the World Health Organization (WHO) INN Programme.

It has been proposed at WHO meetings that biosimilars be given unique names, by the use of a three-letter code (or fantasy suffix) [1].

The majority of EU Member States, however, ‘strongly supported’ the current EU thinking that biosimilars ‘should be closely aligned’ with their reference biological and that an INN qualifier for biosimilars ‘would be contrary to such alignment’.

Several Member States also voiced concern that a distinct INN for biosimilars ‘could undermine the trust of healthcare professionals and the public’ in biosimilars. The Member States reiterated that ‘the same INN should be used for both the reference medicinal products and the biosimilar medicinal products’.

Traceability and attribution of adverse reactions has often been stated as a reason for biosimilars and originator biologicals to have unique names. This was not seen as a problem by the EU Member States. On this subject, Member States, in general, answered that both the brand-name and INN are reported, that batch number is often reported (frequency seems to vary between Member States) and that it is not problematic to identify the biological medicinal products which are the subject of adverse reaction reports.

The Commission Representative committed to report the outcome of the discussion in the WHO INN Programme to the European Commission’s Pharmaceutical Committee.

Related articles

Calls for biosimilars to have same INN at WHO meeting

Fight continues over biosimilar naming standards

Biologicals in EU to be identified by brand names

Naming and interchangeability of biosimilars raised in new survey

Reference

1. GaBI Online - Generics and Biosimilars Initiative. Calls for biosimilars to have same INN at WHO meeting [www.gabionline.net]. Mol, Belgium: Pro Pharma Communications International; [cited 2014 Feb 28]. Available from: www.gabionline.net/Biosimilars/General/Calls-for-biosimilars-to-have-same-INN-at-WHO-meeting

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2014 Pro Pharma Communications International. All Rights Reserved.

Source: Europa

comment icon Comments (0)
Post your comment
Related content
Biosimilars approved in Paraguay
DINAVISA V21J15LT
Biosimilars/General Posted 15/10/2021
Biosimilars approved in Cuba
CECMED V21J07LT
Biosimilars/General Posted 08/10/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010